According to the American CNN Business, Albert Burla is the man who, after the outbreak of the pandemic, it helped bring life back to what looks like normalcy for many of us too, to a large extent due to coronavirus vaccines: one of them is the Pfizer vaccine.
And that is one of the main reasons why CNN has named a Greek businessman of the year: Pfizer chief Albert Burla whose name now stands next to those of previous winners, such as Marfor Benioff of Salesforce (CRM), Brian Cornell of Target and Brian Niccol of Chipotle.
Claimants for the title this time were Lisa Su of AMD, Jim Farley of Ford, Marvin Ellison of Lowe, David Solomon of Goldman Sachs, Sundar Pichai of Alphabet, as well as the head of Tesla of Space X, Elon Musk.
But as CNN notes, "Burla was our choice, for what Pfizer has done at a time when coronavirus vaccines have become mainstream ('vaccine' was the word of the year according to Merriam-Webster) and helped stabilize the US economy. - and in fact, the global ", reports CNN.
"Pfizer has done a lot of good for humanity and we are very, very proud of that", Burla said in an interview with CNN Business. "We could not just save so many lives. But we are enjoying high levels of business reputation right now. "People like us."
According to CNN, Pfizer is not the only company that has developed a coronavirus vaccine. But this Big Pharma leader has become synonymous with the fight against the coronavirus, more so than the BioNTech he worked with or Moderna.
In addition, Pfizer has developed a pill that could drastically reduce the risk of serious complications, hospitalization and death for those infected with the coronavirus. Paxlovid has been approved by the US Food and Drug Administration (FDA). Burla himself, however, explained that the pill does not replace the vaccine.
As for the spread of the new mutation, Burla told CNN that the Pfizer / BioNTech vaccine will control Omicron "quite well", especially if people take three doses.
However, he acknowledged that the company may need to launch a new vaccine specifically targeting Omicron or any future executives. The company is already developing such a vaccine, which Burla estimates will be approved by March.
"If Pfizer needs to produce specific vaccines for the Omicron variant, that will not slow down the production of the vaccines that are being released now," Burla said.
Finally, CNN reports that Pfizer, according to the announcement of its latest results in November, recorded revenues of 13 billion. Dollars from the vaccine in the third quarter of the year and now expects revenue of $ 36 billion for the full year.
protothema.gr